BioSpace News Archive

Groundbreaking clinical and economic impact to be generated NEW HAVEN, Conn., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that preliminary results from its artificial intelligence (AI) initial MVP (Minimal Viable Product) model demonstrate a profound clinical value. The next phase is to develop a working platform expected to become commercial within the next 12-18 months. Background The diagnosis of hematopoietic

Products contain a nitrosamine impurity, N-nitrosodimethylamine (NDMA), above or close to the acceptable limit.

Advantech, a leading provider of medically certified computing products and advanced IoT intelligence systems, will return to the 2020 HIMSS Conference, March 9-13 at the Orange County Convention Center in Orlando, Fla.

Huntington Hospital announced that Deborah Williams has been elected as a returning board member.

Supernus Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that the Company’s management will present an overview and update, as well as host investor meetings, at the 40th Annual Cowen Health Care Conference.

Oerth Bio (pronounced “Earth”), an agricultural biotech company, today announced several key leadership hires.

Prodigo Solutions is a healthcare technology company that improves provider’s financial control and reduces supply chain cost.

Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, announced the closing of its previously announced registered direct offering to certain institutional investors of 1,000,000 ordinary shares of the Company at a purchase price of $8.00 per share for aggregate gross proceeds of $8.0 million.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the fourth quarter and year ended December 31, 2019.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results and business highlights for the fourth quarter and full year ended December 31, 2019.